ReviewPharmaceuticals (Basel, Switzerland)2022
Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 112 citations in OpenAlex.
- Isatin derivatives as potent cholinesterase inhibitors: recent developments and future challenges.RSC advances · 2026Review
- Unlocking the Potential of Isatin Scaffolds in Acetylcholinesterase Inhibition.Archiv der Pharmazie · 2026Review
- Recent trends in anti-Alzheimer's potential of novel biologically active isatin analogues: synthetic strategies, structural activity relationship studies and molecular docking insights.Molecular diversity · 2026Review
- Article
- Isatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice.BMC cancer · 2026Article
- Synthesis and Evaluation of Isatin Analogs as Potential Urease and Tyrosinase Inhibitors: An Approach of Molecular Docking.Chemistry & biodiversity · 2026Article
- Mitochondrial permeability transition pore desensitization by a novel dispiranic derivative prevents cardiac reperfusion injury.Redox biology · 2026Article
- Anticancer potential of fused heterocycles: structural insights and mechanistic advances.Asian biomedicine : research, reviews and news · 2025Article
- Affinity-driven functionalization of magnetic nanoparticles using tryptophan-isatin for potential bio-applications.Nanomedicine (London, England) · 2025Article
- Epoxy-Functionalized Isatin Derivative: Synthesis, Computational Evaluation, and Antibacterial Analysis.Antibiotics (Basel, Switzerland) · 2025Article
- Palladium-supported FeScientific reports · 2025Article
- Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel Coumarin-Triazole-Isatin Hybrids as Selective Butyrylcholinesterase Inhibitors.Molecules (Basel, Switzerland) · 2025Article
- Novel Isatin-Chalcone Hybrid Molecules: Design, Synthesis and Anti-Neuroinflammatory Activity Evaluation.Molecules (Basel, Switzerland) · 2025Article
- Article
- Design and Synthesis of New 5-Methylisatin Derivatives as Potential CDK2 Inhibitors.International journal of molecular sciences · 2025Article
- Synthesis, cytotoxicity, apoptosis-inducing activity and molecular docking studies of novel isatin-podophyllotoxin hybrids.RSC advances · 2025Article
- Design, synthesis,RSC advances · 2025Article
- Novel isatin conjugates endowed with analgesic and anti-inflammatory properties: design, synthesis and biological evaluation.Future medicinal chemistry · 2025Article
- From Structure to Function: Isatin Derivatives as a Promising Class of Antiviral Agents.Current drug targets · 2025Review
- Synthesis and Structure-Activity Relationship (SAR) Studies on New 4-Aminoquinoline-Hydrazones and Isatin Hybrids as Promising Antibacterial Agents.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isatin (1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.